IND Promotion Quandary Again Trips Up Burzynski Research Institute
This article was originally published in The Pink Sheet Daily
The institute has come under scrutiny in the past for how it describes its investigational cancer products, but more mainstream oncology companies have also been cited for jumping the gun with promotional claims for products FDA hasn’t yet approved.
You may also be interested in...
FDA issues untitled letter to CBA Research Inc. for touting the safety and efficacy of CBT-1 as a cancer therapy on the company website although the agency has yet to complete review of an NDA for the drug.
Website suggested that the unapproved cancer immunotherapy was safe and effective, FDA says.
Keryx Biopharmaceuticals is cited for claiming on its website that its investigational oncology drug perifosine is safe and effective.